SpringWorks Therapeutics (SWTX) Competitors

SpringWorks Therapeutics (NASDAQ:SWTX) and Ascendis Pharma A/S (NASDAQ:ASND) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their community ranking, profitability, analyst recommendations, earnings, dividends, risk, institutional ownership, media sentiment and valuation.

Which has more risk & volatility, SWTX or ASND?

SpringWorks Therapeutics has a beta of 0.79, indicating that its stock price is 21% less volatile than the S&P 500. Comparatively, Ascendis Pharma A/S has a beta of 0.54, indicating that its stock price is 46% less volatile than the S&P 500.

Do analysts recommend SWTX or ASND?

SpringWorks Therapeutics currently has a consensus target price of $52.57, indicating a potential upside of 13.55%. Ascendis Pharma A/S has a consensus target price of $204.67, indicating a potential upside of 20.08%. Given Ascendis Pharma A/S's stronger consensus rating and higher possible upside, analysts clearly believe Ascendis Pharma A/S is more favorable than SpringWorks Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
SpringWorks Therapeutics	0 Sell rating(s)	7 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.13
Ascendis Pharma A/S	0 Sell rating(s)	1 Hold rating(s)	14 Buy rating(s)	0 Strong Buy rating(s)	2.93

Does the MarketBeat Community believe in SWTX or ASND?

Ascendis Pharma A/S received 342 more outperform votes than SpringWorks Therapeutics when rated by MarketBeat users. However, 68.39% of users gave SpringWorks Therapeutics an outperform vote while only 66.87% of users gave Ascendis Pharma A/S an outperform vote.

Company	Underperform	Outperform
SpringWorks Therapeutics	Outperform Votes 106 68.39%	Underperform Votes 49 31.61%
Ascendis Pharma A/S	Outperform Votes 448 66.87%	Underperform Votes 222 33.13%

Does the media favor SWTX or ASND?

In the previous week, SpringWorks Therapeutics had 37 more articles in the media than Ascendis Pharma A/S. MarketBeat recorded 50 mentions for SpringWorks Therapeutics and 13 mentions for Ascendis Pharma A/S. Ascendis Pharma A/S's average media sentiment score of 1.07 beat SpringWorks Therapeutics' score of 0.38 indicating that Ascendis Pharma A/S is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
SpringWorks Therapeutics	14 Very Positive mention(s)	8 Positive mention(s)	16 Neutral mention(s)	3 Negative mention(s)	3 Very Negative mention(s)	Neutral
Ascendis Pharma A/S	6 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Is SWTX or ASND more profitable?

Ascendis Pharma A/S has a net margin of -104.54% compared to SpringWorks Therapeutics' net margin of -134.73%. Ascendis Pharma A/S's return on equity of 0.00% beat SpringWorks Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
SpringWorks Therapeutics	-134.73%	-46.74%	-41.12%
Ascendis Pharma A/S	-104.54%	N/A	-39.23%

Which has preferable valuation & earnings, SWTX or ASND?

SpringWorks Therapeutics has higher earnings, but lower revenue than Ascendis Pharma A/S. Ascendis Pharma A/S is trading at a lower price-to-earnings ratio than SpringWorks Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
SpringWorks Therapeutics	$191.59M	18.12	-$325.10M	-$3.48	-13.30
Ascendis Pharma A/S	$363.64M	28.58	-$409.12M	-$7.10	-24.01

Summary

Ascendis Pharma A/S beats SpringWorks Therapeutics on 10 of the 16 factors compared between the two stocks.